PARP inhibitor improves outcomes in ovarian cancer
from Medscape Medical News
The experimental agent olaparib (AstraZeneca) might have a role to play in ovarian cancer. Results from a phase 2 trial have shown that it significantly prolonged progression-free survival in patients with platinum-sensitive relapsed serous ovarian cancer.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063